Camptothecin induced DDX5 degradation increased the camptothecin resistance of osteosarcoma.

Camptothecin induced DDX5 degradation increased the camptothecin resistance of osteosarcoma.
Exp Cell Res. 2020 Jun 22;:112148
Authors: Zhao X, Bao M, Zhang F, Wang W
Abstract
Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents. Unfortunately, chemo-resistance is a huge obstacle in the treatment of OS. However, the underlying molecular mechanisms of OS chemo-resistance still remain unknown. Here we reported that the resistance to camptothecin (cpt) therapy was driven by degradation of DDX5. DDX5 knockdown decreased cell death and DNA damage and recovered cell proliferation in cpt treated 143B cells. Furthermore, we found that DDX5 bound to NONO, a kind of DNA repairing protein, and regulated NONO functions. Our data verified that cpt-induced degradation of DDX5 following by breaking down the protein bound of NONO, which participated in the resistance of cpt. In the summary, according to our results, DDX5 might be a potential therapeutic target for improving clinical outcomes of cpt in OS.
PMID: 32585151 [PubMed - as supplied by publisher]

Source: Experimental Cell Research - June 21, 2020 Category: Cytology Authors: Zhao X, Bao M, Zhang F, Wang W Tags: Exp Cell Res Source Type: research